BMC ophthalmology · 2026
Long-term efficacy of combined phacoemulsification and Hydrus microstent in open-angle glaucoma versus combined-mechanism/primary angle closure glaucoma: a retrospective cohort study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nguyen Kelly C, Ng Eden, Chansangpetch Sunee, Radhakrishnan Sunita, Nguyen Ngoc, Iwach Andrew G, Lin Shan
Аннотация
BACKGROUND: Compare the efficacy of combined Hydrus-cataract surgery in open angle glaucoma (OAG) to combined mechanism glaucoma (CMG) and primary angle closure glaucoma (PACG) over 36 months.
METHODS: A retrospective cohort study of patients with CMG, PACG, or OAG who were treated with 1 or more glaucoma medications prior to surgery. Retrospective review of OAG, CMG, or PACG eyes which underwent combined Hydrus-cataract surgery between Jul 2020-Dec 2021. Regression models were used to evaluate IOP, medication use, success rate (IOP ≤ 18 mmHg without medication) and proportion of medication-free eyes.
RESULTS: The CMG/PACG group (n = 39) had significantly higher IOP reduction from baseline to 36-months than the OAG group (n = 34) (OAG, 15.03 ± 2.90 mmHg to 13.44 ± 3.85 mmHg, p = 0.016; CMG/PACG, 15.62 ± 3.10 to 13.21 ± 2.61 mmHg, p = 0.002) (p = 0.021 for difference). Number of medications was significantly reduced in both groups (OAG, 2.44 ± 1.33 to 1.18 ± 1.40, p < 0.001; CMG/PACG, 2.29 ± 1.27 to 0.87 ± 1.08, p < 0.001) (p = 0.882 for difference). CMG/PACG had higher success rate (49% vs. 29%) and more medication-free eyes (49% vs. 35%) than OAG but these were not statistically significant (p = 0.09 and 0.25, respectively).
CONCLUSIONS: This retrospective study supports the long-term efficacy of combined Hydrus-cataract surgery for CMG/PACG and OAG.
METHODS: A retrospective cohort study of patients with CMG, PACG, or OAG who were treated with 1 or more glaucoma medications prior to surgery. Retrospective review of OAG, CMG, or PACG eyes which underwent combined Hydrus-cataract surgery between Jul 2020-Dec 2021. Regression models were used to evaluate IOP, medication use, success rate (IOP ≤ 18 mmHg without medication) and proportion of medication-free eyes.
RESULTS: The CMG/PACG group (n = 39) had significantly higher IOP reduction from baseline to 36-months than the OAG group (n = 34) (OAG, 15.03 ± 2.90 mmHg to 13.44 ± 3.85 mmHg, p = 0.016; CMG/PACG, 15.62 ± 3.10 to 13.21 ± 2.61 mmHg, p = 0.002) (p = 0.021 for difference). Number of medications was significantly reduced in both groups (OAG, 2.44 ± 1.33 to 1.18 ± 1.40, p < 0.001; CMG/PACG, 2.29 ± 1.27 to 0.87 ± 1.08, p < 0.001) (p = 0.882 for difference). CMG/PACG had higher success rate (49% vs. 29%) and more medication-free eyes (49% vs. 35%) than OAG but these were not statistically significant (p = 0.09 and 0.25, respectively).
CONCLUSIONS: This retrospective study supports the long-term efficacy of combined Hydrus-cataract surgery for CMG/PACG and OAG.